Vertex's Inaxaplin Shows Promising Results in APOL1-Mediated Kidney Disease Trials — Vertex Pharmaceuticals Incorporated

Event summary

Vertex's Phase 2b AMPLIFIED study of inaxaplin showed a 42.7% reduction in UACR in AMKD patients with modest proteinuria.
In AMKD patients with type 2 diabetes, inaxaplin reduced UACR by 17.3% and UPCR by 25.4% at Week 13.
Vertex completed enrollment in the Phase 2/3 AMPLITUDE trial, with interim data expected in early 2027.
Inaxaplin was generally safe and well-tolerated, with no serious adverse events related to the drug.

The big picture

Vertex's positive Phase 2b results for inaxaplin in APOL1-mediated kidney disease (AMKD) reinforce its position in developing targeted therapies for rare genetic conditions. The completion of AMPLITUDE trial enrollment and upcoming interim data in early 2027 could accelerate the drug's path to market, addressing a significant unmet need in a patient population with limited treatment options. The results also highlight Vertex's strategy of leveraging deep biological insights to create transformative medicines.

What we're watching

Regulatory Pathway: Whether the AMPLITUDE interim data in early 2027 will support accelerated approval in the U.S.
Treatment Efficacy: The magnitude of inaxaplin's effect in broader AMKD populations, particularly those with type 2 diabetes.
Market Potential: The pace at which Vertex can address the unmet need in AMKD, affecting approximately 150,000 people in the U.S. and Europe.